Plymouth Meeting, PA – March 03 2015: CRF Health, the leading global provider of eCOA solutions for the life sciences industry, today announced a complete TrialMax® eCOA solution for diabetes clinical trials. Developed with clinicians and patients to optimize usability and compliance, the solution enables investigators to collect patient reported outcome assessments and deliver defensible data, while minimizing patient and site burden. Already being used in four major global diabetes trials, covering 700 investigative sites and 3,250 patients, the powerful solution offers complete integration between patient eDiary entry and blood glucose measurements.
Diabetes trials often have complex protocols which can lead to reduced compliance by overburdened patients. CRF Health's diabetes TrialMax Touch® eDiary leads patients through data collection in an intuitive and fast way. It has been designed to easily fit into patients' lives while providing more compliant data, as well as increased patient retention. The customizable solution enables features to be added or removed depending on the needs of a particular trial, while the reference diary includes 5/7 data collection points which can easily be adapted. Questionnaires are simple to complete, making participating in a trial uncomplicated for patients.
TrialMax Touch® eDiary seamlessly integrates with the Entra Health MyGlucoHealth® wireless glucometer, enabling automatic transfer of measurements to a patient's eDiary. The integration ensures complete and accurate data while reducing the risk of transcription errors. Alerts and notifications can be set-up to remind patients to take their medication and test their blood glucose level, while also providing new basal dose directions from the physician in between site visits. Sites are also made aware of hypoglycemic events via CRF Health's TrialManager®, email or SMS in near real time which provides greater opportunity to take appropriate clinical action. The system also benefits from the ability to integrate with CRF Health's instrument library, allowing sponsors to electronically incorporate common diabetes instruments into the solution.
"CRF Health's experience in eCOA data collection in diabetes studies gives us a wealth of knowledge and experience in helping customers implement solutions that are not only patient-focused, but that ensure the highest levels of quality data", says Katie Garner, Therapeutic Areas Manager, CRF Health. "Our complete solution for diabetes trials is already being used in four impressive trials due to its unique capability to integrate patient diary entry and blood glucose monitoring, helping to ensure studies run as smoothly as possible, while delivering reliable results."
For further information on CRF Health, please visit http://www.crfhealth.com/
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.